📊 LPCN Key Takeaways
Is Lipocine Inc. (LPCN) a Good Investment?
Lipocine faces acute financial distress with revenue collapsed 82% YoY to $2.0M, operating cash burn of $9.8M against only $5.2M cash (6-month runway), and widening net losses of $9.6M. Without immediate capital infusion or dramatic operational reversal, the company risks insolvency and substantial shareholder dilution.
Lipocine shows a steep revenue decline and deeply negative operating profitability, driving substantial free cash outflows. Despite low leverage and strong liquidity ratios, current cash appears insufficient relative to the burn rate, implying likely near-term financing and dilution absent a clear, durable revenue rebound.
Why Buy Lipocine Inc. Stock? LPCN Key Strengths
- Low financial leverage (Debt/Equity 0.06x) provides flexibility for recapitalization
- Modest cash reserves of $5.2M provides short-term liquidity buffer
- Stockholders' equity of $14.5M represents residual asset value
- Strong current and quick ratios indicate solid near-term liquidity
- Low leverage minimizes financial risk and interest burden
- Light liability load supports balance sheet flexibility
LPCN Stock Risks: Lipocine Inc. Investment Risks
- Critical 6-month cash runway at current burn rate of $9.8M annual operating losses
- Catastrophic 82% revenue decline indicates loss of major product/market failure
- Persistent negative operating and free cash flow with no path to profitability visible
- Operating margin of -524.7% and net margin of -487.1% demonstrate extreme unprofitability
- Cash burn exceeds cash on hand, creating near-term dilution/financing risk
- Revenue down 82% YoY highlights concentration and volatility risk
- Persistent negative margins and ROE indicate weak underlying unit economics
Key Metrics to Watch
- Quarterly cash burn rate and months of runway remaining
- Revenue stabilization and near-term product commercialization progress
- Any capital raise announcements and terms of dilution
- Operating cash flow return to positive territory
- Quarterly operating cash burn and months of runway
- Revenue growth and consistency (recurring vs milestone)
Lipocine Inc. (LPCN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.68x current ratio provides a solid financial cushion.
LPCN Profit Margin, ROE & Profitability Analysis
LPCN vs Healthcare Sector: How Lipocine Inc. Compares
How Lipocine Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lipocine Inc. Stock Overvalued? LPCN Valuation Analysis 2026
Based on fundamental analysis, Lipocine Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lipocine Inc. Balance Sheet: LPCN Debt, Cash & Liquidity
LPCN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lipocine Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.69 indicates the company is currently unprofitable.
LPCN Revenue Growth, EPS Growth & YoY Performance
LPCN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $114.6K | -$1.8M | $-0.33 |
| Q2 2025 | $89.6K | $445.0K | $0.10 |
| Q1 2025 | $93.9K | -$1.9M | $-0.35 |
| Q3 2024 | -$3.1M | -$1.8M | $-0.33 |
| Q2 2024 | $55.0K | $445.0K | $0.10 |
| Q1 2024 | $55.0K | $3.5M | $0.66 |
| Q3 2023 | -$3.1M | -$2.4M | $-0.52 |
| Q2 2023 | $55.0K | -$2.6M | $-0.61 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lipocine Inc. Dividends, Buybacks & Capital Allocation
LPCN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lipocine Inc. (CIK: 0001535955)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LPCN
What is the AI rating for LPCN?
Lipocine Inc. (LPCN) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LPCN's key strengths?
Claude: Low financial leverage (Debt/Equity 0.06x) provides flexibility for recapitalization. Modest cash reserves of $5.2M provides short-term liquidity buffer. ChatGPT: Strong current and quick ratios indicate solid near-term liquidity. Low leverage minimizes financial risk and interest burden.
What are the risks of investing in LPCN?
Claude: Critical 6-month cash runway at current burn rate of $9.8M annual operating losses. Catastrophic 82% revenue decline indicates loss of major product/market failure. ChatGPT: Cash burn exceeds cash on hand, creating near-term dilution/financing risk. Revenue down 82% YoY highlights concentration and volatility risk.
What is LPCN's revenue and growth?
Lipocine Inc. reported revenue of $2.0M.
Does LPCN pay dividends?
Lipocine Inc. does not currently pay dividends.
Where can I find LPCN SEC filings?
Official SEC filings for Lipocine Inc. (CIK: 0001535955) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LPCN's EPS?
Lipocine Inc. has a diluted EPS of $-1.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LPCN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lipocine Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LPCN stock overvalued or undervalued?
Valuation metrics for LPCN: ROE of -66.5% (sector avg: 15%), net margin of -487.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LPCN stock in 2026?
Our dual AI analysis gives Lipocine Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LPCN's free cash flow?
Lipocine Inc.'s operating cash flow is $-9.8M, with capital expenditures of $90.1K. FCF margin is -498.4%.
How does LPCN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -487.1% (avg: 12%), ROE -66.5% (avg: 15%), current ratio 6.68 (avg: 2).